Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

Ibrutinib Plus Venetoclax Leads to High Rates of MRD Negativity in Frontline CLL

The combination of ibrutinib with venetoclax – two agents that have been approved for the treatment of chronic lymphocytic leukemia (CLL) – led to...

TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML

In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
On location

Can Women With CML Safely Continue TKIs During Pregnancy?

Most women with chronic myeloid leukemia (CML) who received treatment with tyrosine kinase inhibitors (TKIs) and became pregnant had a normal childbirth, with no...
On location

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.
On location

Flumatinib Superior to Imatinib in Chronic-Phase Chronic Myeloid Leukemia

Flumatinib, a second-generation tyrosine kinase inhibitor (TKI), led to more molecular responses that were also deeper, compared with imatinib, in patients with newly diagnosed...
On location

Should Patients With Hairy Cell Leukemia Receive Delayed or Concurrent Rituximab?

For more than 30 years, the standard firstline treatment of hairy cell leukemia (HCL) has been single-agent purine analog therapy, usually cladribine, but a...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...

Venetoclax Approved for CLL and SLL

The U.S. Food and Drug Administration (FDA) approved venetoclax, in combination with obinutuzumab, for the treatment of adult patients with chronic lymphocytic leukemia (CLL)...
You Make the Call

Is there a genetic risk for familial CLL?

This month, Kanti R. Rai, MD, discusses familial chronic lymphocytic leukemia. And don't forget to check out next month's clinical dilemma - send in your...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.